Daiichi Pharmaceutical Co., Ltd.

Daiichi Seiyaku Co., Ltd.

Nobuyuki Higashihashi

Katsuichi Sakano

Isao Hayakawa

Shohgo Atarashi

Masazumi Imamura

Shuichi Yokohama

Masayuki Ohshima

Ryuji Hashimoto

The effects of endogenous insulin-like growth factor can be appreciated by administering compounds capable of increasing free IGF in living bodies. Compounds are described which can elevate the concentration of unbound IGF by converting endogenous IGF (insulin-like growth factor) into free, biologically active IGF or elevating the concentration of the complex of IGF and IGFBP (insulin-like growth factor binding protein) in living bodies. Medicaments can be prepared containing these compounds or these compounds may be used in methods for the prevention and or treatment of IGF-responsive diseases such as diabetes, amyotrophic lateral sclerosis, or osteoporosis.

Composition of an endogenous insulin-like growth factor-II derivative

An optically action pyridobenzoxazine derivative, a process for preparing the same and a novel intermediate useful for preparing the optically active pyridobenzoxazine derivative are disclosed. The optically active pyridobenzoxazine derivative possesses increased antimicrobial activity and reduced toxicity. The intermediate is useful for preparing such optically active pyridobenzoxazine derivatives such as Ofloxacin and anolog compounds.

Optically active pyridobenzoxazine derivatives and intermediates thereof

Optically active pyridobenzoxazine derivatives and anti-microbial use

Growing community of inventors

Tokyo, Japan

Nobuyuki Higashihashi